| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Clinical Medicine and Neurology (Drs. Zivadinov, De Masi, Nasuelli, Cazzato, and Zorzon), Radiology (Drs. Ukmar and Pozzi–Mucelli), and Electrical, Electronics, and Computer Science (A. Grop), University of Trieste, Italy; and Mellen Center (Dr. Rudick), Department of Neurology, Cleveland Clinic Foundation, OH.
Address correspondence and reprint requests to Dr. R. Zivadinov, Neurological Clinic, Cattinara Hospital, Strada di Fiume, 447-34149 Trieste, Italy; e-mail: zivadinov{at}hotmail.com
Background: IV methylprednisolone (IVMP) has been used to treat relapses in patients with relapsing-remitting (RR) MS, but its effect on disease progression is not known. Furthermore, there are no data on the impact of IVMP on T1 black holes or whole-brain atrophy. Objective: To determine the effect of IVMP on MRI measures of the destructive pathology in patients with RR-MS and secondarily to determine the effect of IVMP on disability progression in patients with RR-MS. Methods: The authors conducted a randomized, controlled, single-blind, phase II clinical trial of IVMP in patients with RR-MS. Eighty-eight patients with RR-MS with baseline Expanded Disability Status Scale (EDSS) scores of 
5.5 were randomly assigned to regular pulses of IVMP (1 g/day for 5 days with an oral prednisone taper) or IVMP at the same dose schedule only for relapses (IVMP for relapses) and followed without other disease-modifying drug therapy for 5 years. Pulsed IVMP was given every 4 months for 3 years and then every 6 months for the subsequent 2 years. Patients had quantitative cranial MRI scans at study entry and after 5 years and standardized clinical assessments every 4 to 6 months. Results: Eighty-one of 88 patients completed the trial as planned, and treatment was well tolerated. Baseline demographic, clinical, and MRI measures were well matched in the two study arms. Patients on the pulsed IVMP arm received more MP than patients on the control arm of the study (p < 0.0001). Mean change in T1 black hole volume favored pulsed IVMP therapy (+1.3 vs +5.2 mL; p < 0.0001), as did mean change in brain parenchymal volume (+2.6 vs -74.5 mL; p = 0.003). There was no significant difference between treatment arms in the change in T2 volume or annual relapse rate during the study. However, there was significantly more EDSS score worsening in the control group, receiving IVMP only for relapses. There was a 32.2% reduction (p 0.0001) in the probability of sustained EDSS score worsening in the pulsed MP arm compared with the relapse treatment arm. At the end of the study, EDSS was better in the pulsed MP group (1.7 vs 3.4; p < 0.0001). Prolonged treatment with pulsed IVMP was safe and well tolerated; only two patients dropped out for toxic side effects over 5 years. Conclusions: In patients with RR-MS, treatment with pulses of IVMP slows development of T1 black holes, prevents or delays whole-brain atrophy, and prevents or delays disability progression. A phase III study of IVMP pulses is warranted.
This article has been cited by other articles:
|
|
 |
|
  E. A. Yeh, B. Weinstock-Guttman, M. Ramanathan, D. P. Ramasamy, L. Willis, J. L. Cox, and R. Zivadinov Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis Brain, November 5, 2009; (2009) awp278v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zivadinov, B. Weinstock-Guttman, K. Hashmi, N. Abdelrahman, M. Stosic, M. Dwyer, S. Hussein, J. Durfee, and M. Ramanathan Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis Neurology, August 18, 2009; 73(7): 504 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Havrdova, R Zivadinov, J Krasensky, M. Dwyer, I Novakova, O Dolezal, V Ticha, L Dusek, E Houzvickova, J. Cox, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis Multiple Sclerosis, August 1, 2009; 15(8): 965 - 976. [Abstract] [PDF]
|
|
|
|
 |
|
 R Zivadinov, M Zorzon, B Weinstock-Guttman, M Serafin, A Bosco, A Bratina, C Maggiore, A Grop, M A Tommasi, B Srinivasaraghavan, et al. Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Antulov, B Weinstock-Guttman, J. Cox, S Hussein, J Durfee, C Caiola, M. Dwyer, N Bergsland, N Abdelrahman, M Stosic, et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures Multiple Sclerosis, March 1, 2009; 15(3): 345 - 354. [Abstract] [PDF]
|
|
|
|
|
|
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis Neurology, July 8, 2008; 71(2): 136 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Horakova, J L Cox, E Havrdova, S Hussein, O Dolezal, D Cookfair, M G Dwyer, Z Seidl, N Bergsland, M Vaneckova, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study J. Neurol. Neurosurg. Psychiatry, April 1, 2008; 79(4): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Zivadinov, A.C. Banas, V. Yella, N. Abdelrahman, B. Weinstock-Guttman, and M.G. Dwyer Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zivadinov, B. Weinstock-Guttman, R. Benedict, M. Tamano-Blanco, S. Hussein, N. Abdelrahman, J. Durfee, and M. Ramanathan Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor Hum. Mol. Genet., November 15, 2007; 16(22): 2659 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. T. Bergh The clock keeps ticking for intravenous methylprednisolone J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 788 - 788. [Full Text] [PDF]
|
|
|
|
|
|
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al. I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Multiple Sclerosis, May 1, 2007; 13(4): 490 - 501. [Abstract] [PDF]
|
|
|
|
 |
|
 B. A. Choudry and J. W. Chan An Update on Monoclonal Antibody Therapies in Multiple Sclerosis Journal of Pharmacy Practice, April 1, 2007; 20(2): 167 - 180. [Abstract] [PDF]
|
|
|
|
|
|
J H Simon Brain atrophy in multiple sclerosis: what we know and would like to know Multiple Sclerosis, November 1, 2006; 12(6): 679 - 687. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Chadha, B. Weinstock-Guttman, R. Zivadinov, K. Bhasi, J. Muhitch, J. Feichter, M. Tamano-Blanco, N. Abdelrahman, J. Ambrus Sr, F. Munschauer, et al. Interferon Inhibitory Activity in Patients With Multiple Sclerosis Arch Neurol, November 1, 2006; 63(11): 1579 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. B. Benedict, J. M. Bruce, M. G. Dwyer, N. Abdelrahman, S. Hussein, B. Weinstock-Guttman, N. Garg, F. Munschauer, and R. Zivadinov Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol, September 1, 2006; 63(9): 1301 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wang, R. Allie, K. Conant, N. Haughey, J. Turchan-Chelowo, K. Hahn, A. Rosen, J. Steiner, S. Keswani, M. Jones, et al. Granzyme B mediates neurotoxicity through a G-protein-coupled receptor FASEB J, June 1, 2006; 20(8): 1209 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C.A. Steens, G. M. Steup-Beekman, G. P.Th. Bosma, F. Admiraal-Behloul, H. Olofsen, J. Doornbos, T. W.J. Huizinga, and M. A. van Buchem The Effect of Corticosteroid Medication on Quantitative MR Parameters of the Brain AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2475 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krapf, S. P. Morrissey, O. Zenker, T. Zwingers, R. Gonsette, H. -P. Hartung, and the MIMS Study Group Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial Neurology, September 13, 2005; 65(5): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J Fox, E. Fisher, J. Tkach, J.-C. Lee, J. A Cohen, and R. A Rudick Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications Multiple Sclerosis, April 1, 2005; 11(2): 140 - 145. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Rizvi and K. Bashir Other therapy options and future strategies for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S47 - S54. [Abstract] [Full Text]
|
|
|
|
|
|
A. Langer-Gould, H. H. Moses, and T. J. Murray Strategies for managing the side effects of treatments for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S35 - S41. [Abstract] [Full Text]
|
|
|
|
|
|
L. Locatelli, R. Zivadinov, A. Grop, and M. Zorzon Frontal parenchymal atrophy measures in multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 562 - 568. [Abstract] [PDF]
|
|
|
|
|
|
September 28 Highlight and Commentary Neurology, September 28, 2004; 63(6): 945 - 945. [Full Text] [PDF]
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347. [Abstract] [PDF]
|
|
|
|
|
|
I. Pirko and M. Rodriguez Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial Arch Neurol, July 1, 2004; 61(7): 1148 - 1149. [Full Text] [PDF]
|
|
|
|
|
|
J. Sharma, M. P. Sanfilipo, R. H. B. Benedict, B. Weinstock-Guttman, F. E. Munschauer III, and R. Bakshi Whole-Brain Atrophy in Multiple Sclerosis Measured by Automated versus Semiautomated MR Imaging Segmentation AJNR Am. J. Neuroradiol., June 1, 2004; 25(6): 985 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients Neurology, March 9, 2004; 62(5): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Diem, M. Hobom, K. Maier, R. Weissert, M. K. Storch, R. Meyer, and M. Bahr Methylprednisolone Increases Neuronal Apoptosis during Autoimmune CNS Inflammation by Inhibition of an Endogenous Neuroprotective Pathway J. Neurosci., August 6, 2003; 23(18): 6993 - 7000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S J Hickman, R Kapoor, S J Jones, D R Altmann, G T Plant, and D H Miller Corticosteroids do not prevent optic nerve atrophy following optic neuritis J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1139 - 1141. [Full Text] [PDF]
|
|
|
|
|
|
F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Leigh, J Ostuni, D Pham, A Goldszal, B K Lewis, T Howard, N Richert, H McFarland, and J A Frank Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences Multiple Sclerosis, October 1, 2002; 8(5): 420 - 429. [Abstract] [PDF]
|
|
|
|
|
|
D. L. Arnold and P.M. Matthews MRI in the diagnosis and management of multiple sclerosis Neurology, April 23, 2002; 58(90084): S23 - 31. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
